Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence

Background Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Irina Surovtsova, Felix J. F. Herth, Daria B. Kokh, Philipp Morakis
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2025-12-01
coleção:	Pulmonology
Assuntos:	mNSCLC KEYNOTE 189 real world data cancer registry bone metastases
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/25310429.2025.2457856
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!